Early development of pembrolizumab-induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
© 2022 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology..
Herein, we report the case of a 48-year-old woman with metastatic thymoma who developed fulminant myositis with cardiotoxicity after one cycle of pembrolizumab treatment. She presented with severe muscle weakness and dyspnea, and her laboratory test results revealed increased muscle and cardiac enzyme levels. Despite an urgent initiation of systemic steroids, her muscle weakness and hypercapnia worsened, for which intravenous immunoglobulin G was initiated. However, hypercapnia did not improve, but the patient recovered completely after plasma exchange. Patients with thymic neoplasms could be susceptible to fulminant forms of immune-related adverse effects because they lack normal thymic physiology. Clinicians must not hesitate to consider immunoglobulin G administration and plasma exchange therapy as the next treatment steps for steroid-refractory patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Respirology case reports - 10(2022), 9 vom: 01. Sept., Seite e01025 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jang, Soo Yeon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 30.08.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/rcr2.1025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345516117 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345516117 | ||
| 003 | DE-627 | ||
| 005 | 20231226025230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rcr2.1025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345516117 | ||
| 035 | |a (NLM)36034177 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jang, Soo Yeon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early development of pembrolizumab-induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. | ||
| 520 | |a Herein, we report the case of a 48-year-old woman with metastatic thymoma who developed fulminant myositis with cardiotoxicity after one cycle of pembrolizumab treatment. She presented with severe muscle weakness and dyspnea, and her laboratory test results revealed increased muscle and cardiac enzyme levels. Despite an urgent initiation of systemic steroids, her muscle weakness and hypercapnia worsened, for which intravenous immunoglobulin G was initiated. However, hypercapnia did not improve, but the patient recovered completely after plasma exchange. Patients with thymic neoplasms could be susceptible to fulminant forms of immune-related adverse effects because they lack normal thymic physiology. Clinicians must not hesitate to consider immunoglobulin G administration and plasma exchange therapy as the next treatment steps for steroid-refractory patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a myositis | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 4 | |a plasma exchange | |
| 650 | 4 | |a thymoma | |
| 700 | 1 | |a Lee, Sung Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hye Lim |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Juwhan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology case reports |d 2013 |g 10(2022), 9 vom: 01. Sept., Seite e01025 |w (DE-627)NLM244269440 |x 2051-3380 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:9 |g day:01 |g month:09 |g pages:e01025 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rcr2.1025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 9 |b 01 |c 09 |h e01025 | ||